Back to Search Start Over

Decade-long leukaemia remissions with persistence of CD4 + CAR T cells.

Authors :
Melenhorst JJ
Chen GM
Wang M
Porter DL
Chen C
Collins MA
Gao P
Bandyopadhyay S
Sun H
Zhao Z
Lundh S
Pruteanu-Malinici I
Nobles CL
Maji S
Frey NV
Gill SI
Loren AW
Tian L
Kulikovskaya I
Gupta M
Ambrose DE
Davis MM
Fraietta JA
Brogdon JL
Young RM
Chew A
Levine BL
Siegel DL
Alanio C
Wherry EJ
Bushman FD
Lacey SF
Tan K
June CH
Source :
Nature [Nature] 2022 Feb; Vol. 602 (7897), pp. 503-509. Date of Electronic Publication: 2022 Feb 02.
Publication Year :
2022

Abstract

The adoptive transfer of T lymphocytes reprogrammed to target tumour cells has demonstrated potential for treatment of various cancers <superscript>1-7</superscript> . However, little is known about the long-term potential and clonal stability of the infused cells. Here we studied long-lasting CD19-redirected chimeric antigen receptor (CAR) T cells in two patients with chronic lymphocytic leukaemia <superscript>1-4</superscript> who achieved a complete remission in 2010. CAR T cells remained detectable more than ten years after infusion, with sustained remission in both patients. Notably, a highly activated CD4 <superscript>+</superscript> population emerged in both patients, dominating the CAR T cell population at the later time points. This transition was reflected in the stabilization of the clonal make-up of CAR T cells with a repertoire dominated by a small number of clones. Single-cell profiling demonstrated that these long-persisting CD4 <superscript>+</superscript> CAR T cells exhibited cytotoxic characteristics along with ongoing functional activation and proliferation. In addition, longitudinal profiling revealed a population of gamma delta CAR T cells that prominently expanded in one patient concomitant with CD8 <superscript>+</superscript> CAR T cells during the initial response phase. Our identification and characterization of these unexpected CAR T cell populations provide novel insight into the CAR T cell characteristics associated with anti-cancer response and long-term remission in leukaemia.<br /> (© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)

Details

Language :
English
ISSN :
1476-4687
Volume :
602
Issue :
7897
Database :
MEDLINE
Journal :
Nature
Publication Type :
Academic Journal
Accession number :
35110735
Full Text :
https://doi.org/10.1038/s41586-021-04390-6